P645: IBRUTINIB FOR TREATMENT OF RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A MATCHING-ADJUSTED INDIRECT COMPARISON OF 3 RANDOMIZED PHASE 3 TRIALS

• Paolo Ghia,
• Talha Munir,
• Jan Burger,
• John Seymour,
• Kerry Rogers,
• Hsin-Hui Huang,
• Carol Moreno,
• Lynne Neumayr,
• Chris Abbazio,
• Jeff Sharman

Affiliations

Paolo Ghia

1 Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, MIlan, Italy

Talha Munir

2 St James’s University Hospital, Leeds, United Kingdom

Jan Burger

3 The University of Texas MD Anderson Cancer Center, Houston, TX, United States

John Seymour

4 Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia

Kerry Rogers

5 The Ohio State University, Columbus, OH, United States

Hsin-Hui Huang

6 AbbVie, North Chicago, IL, United States

Carol Moreno

7 Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

Lynne Neumayr

8 AbbVie, South San Francisco, United States

Chris Abbazio

9 Pharmacyclics LLC, an AbbVie Company, South San Francisco, United States

Jeff Sharman

10 Willamette Valley Cancer Institute and Research Center, Eugene, OR, United States